None listed
Conditions
Brief summary
This study will investigate the use of eye tracking for identifying variations in eye movements with physiological changes. This includes caffeine and alcohol intake – certain medications and substances affect the central nervous system and alertness, and therefore overall eye movement control, which we hypothesise to alter gaze behaviour. We hypothesise that eye tracking dysfunction (involuntary eye movements which occur when a person looks at a rapidly moving target) measured by novel methods will provide a rapid, non-invasive test to diagnose and monitor prognosis of certain conditions such as mild traumatic brain injury, and other neurological and eye diseases.
Interventions
The interventional study involves assessing eye movements with a portable eye tracking device to investigate the effect of caffeine and alcohol on eye movement control.
The portable eye tracking device consists of an eye piece and internal screen and camera. One version of the device will be handheld, while the other version of the device is head mounted (similar to a virtual reality headset). The participant will be allocated one of the device versions for the eye tracking assessment. For the
The interventional study involves assessing eye movements with a portable eye tracking device to investigate the effect of caffeine and alcohol on eye movement control. The portable eye tracking device consists of an eye piece and internal screen and camera. One version of the device will be handheld, while the other version of the device is head mounted (similar to a virtual reality headset). The participant will be allocated one of the device versions for the eye tracking assessment. For the handheld device, the participant will be instructed to hold the device eye piece against their eyes, which will be the only part of the device that contacts their face. For the head mounted device, the researcher will place the head strap on their head. The participant will be instructed to hold the device eye piece against their eye, which will be the only part of the device that contacts their face, and follow a target (moving dot) on a screen that will play a series of eye tracking tasks. A video recording of the eye movements in each eye is captured and analysed. Healthy participants will have baseline eye tracking prior to any alcohol or caffeine consumption, and repeat eye tracking every 30 minutes up to 3 hours after alcohol or caffeine consumption. The caffeine group will also have a late time point on the same day, 8 hours post-intake. The alcohol group will also undergo eye tracking the next morning (in the absence of caffeine), along with Blood Alcohol Concentration (BAC) measurements (i.e. to measure “hangover” effect, if any). The following groups are: Caffeine dosage and groups: 1. Coffee 63mg (1 shot espresso) 2. Coffee 125mg (2 shot espresso) 3. Coffee 190mg (3 shot espresso) 4. Red bull energy drink (80mg) 5. Control group: Decaffeinated coffee (2mg caffeine) Alcohol groups: 1. 0.01-0.05% BAC as determined via breathalyser. 2. 0.06-0.10% BAC 3. 0.11-0.15% BAC 4. 0.16-0.20% BAC 5. Control group: Non-alcoholic beverage e.g. (0% alcohol content soda)
Sponsors
VRF Vault Ltd
Study design
Allocation
Randomised controlled trial
Primary purpose
Diagnosis
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Healthy participants, aged 18 and above from the community.
Exclusion criteria
Those with any active or past neurological pathology (e.g. trauma, vascular, epilepsy, schizophrenia), cardiovascular risk, liver disease, pregnancy, and diabetes will be excluded. We will also exclude those with refractive errors > +/- 5.00 Dioptres. Participants taking any medication that interferes with alcohol or caffeine consumption will be excluded, along with alcohol dependency, frequent alcohol intake (>4x/week), or substance misuse disorders.
Outcome results
None listed